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Abstract
Background: Being overweight or obese following breast cancer diagnosis can increase cancer recurrence and
mortality, so effective interventions for weight loss in this group could enhance survival. A pilot randomised
controlled trial was conducted to assess whether a weight loss programme comprising generic Weight Watchers®
referral offered to women treated for breast cancer with or without additional breast cancer-tailored dietetic
support is feasible and shows promise for improving weight and quality of life (QoL).
Methods: Participants were randomly allocated to 3 groups: Weight Watchers® referral (for 12 sessions of meetings
and digital tools) plus 5 breast cancer-tailored dietitian-led group support sessions (WW Plus: n = 14), Weight
Watchers® referral only (WW: n = 16) or control (Weight Watchers® referral after 3 months, n = 15). Feasibility was
assessed based on retention rate, recruitment and randomisation process, meeting attendance, suitability of the
setting and outcome measurement tools, unintended consequences, cost and observations of the dietetic sessions.
Outcomes were measured at 0, 3 (‘trial exit’) and 12 months post intervention.
Results: The response rate to the invitation was 43% (140/327) of whom 58 were eligible and 45 (median age 61.
0 years; body mass index 30.2 kg/m2) were randomised. Data from 38 (84%) and 30 (67%) participants were available at
trial exit and 12 months respectively. Feasibility issues included slow recruitment process, lack of blinding throughout,
weighing scales not measuring > 150 kg, lack of clear instructions for completing QoL questionnaire and workload and
time pressures in delivering dietetic sessions. Participants had good attendance rate at group meetings and no serious
unintended consequences were reported. WW Plus was most expensive to run. Mean (95% CI) weight change at trial
exit was − 3.67 kg (− 5.67, − 2.07) in WW Plus, − 6.03 kg (− 7.61, − 4.44) in WW group and + 0.19 kg (− 1.45, + 1.83) in
control group. About 40% of the WW Plus, 64% of the WW group and 56% of the control group lost ≥ 5% of their
baseline weight by 12 months. All groups showed promise for improving QoL at trial exit but only the WW group
maintained significant improvements from baseline at 12 months.
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Conclusions: The trial procedures were feasible, with some modifications. This pilot trial indicates the benefits of
providing free WW vouchers for weight loss maintenance and improving QoL but provided no evidence that including
additional dietetic support would add any extra value. Further research with WW with long-term follow-up should be
undertaken to assess weight loss sustainability and benefit on health outcomes in this patient group.
Trial registration: ISRCTN-29623418.
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Background
Breast cancer is the most common cancer among women
worldwide, accounting for 25% of all female cancer cases
and 12% of all cancer cases in 2012 [1, 2]. There are an es-
timated 1.67 million new cases of breast cancer and around
522,000 deaths from breast cancer each year [3]. The ma-
jority of women (50–96%) gain weight following breast
cancer diagnosis and its treatments, with an average weight
gain of 2.5–6.2 kg within 2 years of diagnosis [4–6].
Post-diagnosis weight gain is mainly associated with life-
style changes (i.e. reduced energy expenditure and/or in-
creased dietary intake) related to various treatment-related
side-effects such as fatigue, change in sense of taste, psy-
chological distress, functional impairments and poor qual-
ity of life (QoL) (Irwin, Melinda [53] L 2003) [4, 6, 8]
(Maley, Mary 2013 [54]). In contrast, weight loss following
breast cancer diagnosis is not as common as weight gain
[7]. The weight gain pattern observed in women with
breast cancer is much higher than healthy women in gen-
eral in the United Kingdom (UK) population in whom,
body mass index (BMI) increases on average about 0.1
BMI point (approximately 0.3 kg) per year [8, 9].
Being overweight or obese following diagnosis of
breast cancer is associated with metabolic and hormonal
profiles which may stimulate breast cancer growth in
both pre- and post-menopausal survivors [10, 11].
Several systematic reviews and meta-analyses have found
a significant association between weight gain of more than
5% and increased hazard of both breast cancer-related
and all-cause mortality compared to women who maintain
weight following diagnosis [10–12], with evidence of a
dose-response relationship and a suggestion of a larger ef-
fect among women with a pre-diagnosis BMI < 25 kg/m2
[10]. Collectively, these findings suggest that efforts to
minimise weight gain after diagnosis may improve survival
[13]. Two large randomised controlled trials (RCTs) asses-
sing the adoption of a diet that was either high in vegeta-
bles, fruit and fibre and low in fat (n = 3088, 7.3 year
follow-up) (Pierce, John P 2007 [55]) or reduced fat (n =
2437, median 5-year follow-up) (RT, Chlebowski 2006
[56]), concluded that changes in dietary pattern alone
(without any weight loss) is not sufficient to reduce add-
itional breast cancer events or mortality in breast cancer
survivors. Although the number of trials testing lifestyle
interventions in breast cancer survivors is growing, it is
still unknown whether intentional weight loss improves
breast cancer-related outcomes (long-term disease-free
survival, reduced overall mortality) in survivors [4, 14, 15].
There is no specific guidance for weight management
in breast cancer survivors. Leading cancer organisations
recommend that cancer survivors achieve and maintain
a healthy body weight using similar strategies to those
available for the general adult population [16, 17] with a
combination of dietary, physical activity and behavioural
strategies [18, 19]. The time after a cancer diagnosis has
been described as a ‘teachable moment’ for health pro-
motion such as weight management [20]. It could be
that cancer patients are more motivated to engage in
healthy lifestyle behaviours for a better prognosis [20].
However, previous research has found that adherence to
recommended health behaviours for this population is
less than optimal [21] with lack of support from the
medical team, lack of knowledge regarding a healthy diet
and its benefits, lack of access to available information
and guidance, poor motivation, as well as various
co-morbidities (e.g. functional impairment) cited as bar-
riers to change [22–24]. Cancer survivors are a vulnerable
population and weight loss can be extremely difficult due
to the physical and mental challenges of cancer diagnosis
and its treatment. Therefore, identifying and suggesting
feasible weight loss components in women treated for
breast cancer and investigating the impact of weight loss
on longer-term prognosis is important [25].
The overall purpose of this study was to assess the
feasibility and practicality of conducting a RCT of a
weight loss programme in women treated for breast can-
cer and hence, replicating this trial to a definitive trial.
The study was guided by the Medical Research Council
(MRC) framework for developing and evaluating com-
plex interventions [26]. Preparatory work involved a sys-
tematic review of RCTs targeting weight loss in women
treated for breast cancer, synthesis of other relevant evi-
dence (e.g. current recommendations for cancer survivors
and the general population of adults for supporting weight
loss-management) and a mixed methods study [focus
group meetings (n = 15), survey (n = 139) and interviews
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(n = 20)] with the target population to understand their ex-
periences and future preferences of a weight loss
programme [27–30]. A summary of the findings of the pre-
liminary study is presented in Additional file 1: Appendix 1.
Referral to Weight Watchers® (WW) were included as
an intervention in order to address some of the modifi-
able barriers identified in the preliminary study, such as
free access to a weight loss programme, education and
social support for weight loss. The WW programme is
based on the National Institute for Health and Care
Excellence (NICE) guideline for obesity management
and 14 various behaviour change techniques (BCTs)
[31]. It has been found to be effective for clinically
significant weight loss in the general adult population
[32, 33] as well as in women treated for breast cancer
[34], when free WW vouchers were given. In addition, a
group-based programme similar to the format of many
commercial weight management programmes was pre-
ferred by our preliminary study participants due to their
flexibility (e.g. available at different times and days of the
week, the option to attend a full session or drop in for
getting weighed) and coaches have experienced a weight
loss journey themselves. At the time of this study, WW
referral was available through the UK primary care refer-
ral scheme to provide weight loss support to overweight
and obese patients. The original plan was that the WW
leaders would receive additional training from a dietitian
and breast care nurses to deliver breast cancer-related
extra support for breast cancer patients. However, WW
would not allow any modification of WW regular group
meeting contents and training of the leaders by anyone
other than WW. As a result, a breast cancer-tailored
dietetic-led group support programme was developed as
an additional component to be delivered by a dietitian
and a breast care nurse along with the WW programme
to check its feasibility and whether it shows promise for
greater weight loss and improvement in QoL compared
to generic WW referral only or a control group. WW
programme was the main component for weight loss
and the dietetic-led sessions were aimed to provide so-
cial support through being with people who had experi-
enced similar issues, encourage self-monitoring of
lifestyle behaviour to maintain a healthy weight and im-
prove knowledge by providing information related to
diet, physical activity and healthy lifestyle.
This article reports the feasibility of the trial proce-
dures and the outcomes related to participants in the
pilot trial. A pilot trial is a smaller version of a future de-
finitive trial in which all or some parts of the interven-
tion to be evaluated and other processes (e.g.
randomisation) to be undertaken in a future trial is/are
carried out (piloted) to check its feasibility (Eldridge,
Sandra M 2016 [57]). The research question asked in
our pilot trial was: Is conducting a weight loss
programme comprising generic WW referral offered to
women treated for breast cancer with or without add-
itional breast cancer-tailored dietetic support feasible?
The primary outcome assessed was feasibility of the trial
procedures from recruitment until trial exit. The specific
objectives included assessing the facilitators and barriers
towards conducting, assessing and/or delivering the trial
components. The secondary outcomes assessed were




A pragmatic single-centre pilot parallel group rando-
mised controlled trial RCT, involving three arms: WW
Plus (Weight Watchers® referral to 12 sessions of com-
munity meetings and digital tools, plus 5 breast
cancer-tailored dietitian-led group support), WW group
(Weight Watchers® referral) and control group (Weight
Watchers® referral after 3 months) (discussed under
‘Trial arms’ section), was designed to evaluate the whole
process and inform decisions about whether a future
full-scale RCT is feasible and shows promise.
This trial was conducted in the North East of Scotland
between September 2013 and June 2015.
The trial was run in two cohorts: cohort 1 (November
2013–February 2013) and cohort 2 (March–June 2014)
to avoid a long interval between recruitment, baseline
meeting and trial entry. Changes in body weight and
QoL were assessed at the trial exit which was week 14
(post randomisation) for the WW Plus group and week
12 (post randomisation) for the WW and control
groups. The intervention period was longer for the WW
Plus compared to other arms because participants
attended two sessions of the dietetic-led group support
programme before they received the WW referral pack
for 12 sessions. An opportunity to follow-up participants
at 12 months post intervention (March–June 2015)
arose subsequent to the initial protocol. An amendment
to the protocol was made which the ethics committee ap-
proved. There were no contacts with the research team
until they were invited for further assessment at 12 months.
It should be noted that there was lack of blinding for allo-
cation, outcome assessment and analysis throughout the
trial because this was a PhD project for a researcher (RN)
who was the main contact with participants.
Recruitment and group allocation
Women attending the Breast Clinic at Aberdeen Royal
Infirmary (ARI, the main hospital in Aberdeen City) be-
tween September 2013 and January 2014 were sent an
invitation letter from a senior breast cancer specialist
(SDH) along with a patient information sheet and an
opt-in form 2–3 weeks prior to their next scheduled
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appointment. Women who were interested in taking part
in the trial sent the opt-in form back to the researcher
(RN) in a postage paid envelope. Based on this opt in
form, eligible participants were contacted to attend a base-
line meeting.
The inclusion/exclusion criteria before randomisation
are given in Table 1.
Formal sample size power calculations were not car-
ried out as this was a pilot study and the focus was not
on formal testing of hypotheses but estimating parameters
for a full-scale future trial [35]. It has been suggested that
the sample of a pilot study should be representative of the
target population and large enough to estimate parameters
for a future trial [35] (Shanyinde M. 2011 [58]). The initial
target was to recruit 30 participants per arm as the Chief
Scientist Office (Scottish Government Health Directorates)
guidelines for developing pilot studies suggests (Chief Sci-
entist Office 2014 [59]). The opt-in form asked potential
participants to provide information on their current
weight and height, year of diagnosis, recent participation
in commercial weight management programmes and pos-
sibility of pregnancy, to assess their eligibility.
Baseline meeting
Potential participants were invited to attend a one-
to-one baseline meeting with the researcher (RN) at the
Maggie’s Cancer Support Centre located within the ARI
health campus; an attractive setting for its sensory as-
pects with easy access to facilities (i.e. regular public
transport and parking spaces for the centre’s use). Reim-
bursement for travel expenses incurred by participating
in the trial was offered to all participants. At the baseline
meeting, participants who agreed to take part were asked
to give their informed consent (written) and, for con-
senting participants, their height, weight and QoL were
then measured to confirm eligibility based on BMI and
so that randomisation could be carried out with mini-
misation of the differences in BMI between groups.
These methods were used to avoid recruiting partici-
pants with a ≤ healthy BMI and/or to minimise
differences between groups. We learned from previous
work that often patients could not remember their
current height and weight or reported a weight and/or
height that were taken a long time ago [47, 48]. Height
was measured to the nearest 0.1 cm with a Leicester port-
able height measure (Marsden, UK), without shoes and
with the back straight and the head in the Frankfurt plane.
Weight was measured to the nearest 0.1 kg with electronic
scales (SECA, Model 803, Hamburg, Germany) with partic-
ipants wearing light clothing and no shoes. BMI (kg/m2)
was calculated as weight (kg) / height (m)2.
The Functional Assessment of Cancer Therapy-Breast
(FACT-B) questionnaire (version 4) was used to assess QoL
as it is a validated instrument for cancer survivors and has
also shown good sensitivity to change [36, 37]. It has a
5-point Likert-type response scale for 36-item measures that
cover 4 Functional Assessment of Cancer Therapy-General
(FACT-G) subscales: Physical Well-Being (PWB), Social/
Family Well-Being (SWB), Emotional Well-Being (EWB)
and Functional Well-Being (FWB) along with an additional
Breast Cancer-Specific (BCS) subscale. The BCS subscale as-
sesses symptoms/concerns of particular relevance to breast
cancer (e.g. body image, arm swelling and tenderness).
Group allocation
Following the baseline meeting, each participant was rando-
mised on a 1:1:1 ratio by a researcher (RN) using an
in-house computer programme which allocated participants
minimising differences between the groups in terms of
three categorical variables: baseline BMI (< 30/≥ 30 kg/m2),
age (< 60/≥ 60 years) and time since diagnosis (< 1/≥ 1 year).
Participants were contacted by telephone (by a researcher,
RN) to inform them of their group allocation and arrange
subsequent meetings.
Trial arms
WW Plus (Weight Watchers referral plus breast
cancer-tailored dietitian-led group support) Partici-
pants were invited to attend five breast cancer-tailored
Table 1 Inclusion/exclusion criteria
Inclusion criteria ▪ Women who had completed initial treatment (surgery, chemotherapy and/or radiotherapy) for breast cancer
▪ Age ≥ 18 years
▪ Body mass index ≥ 25 kg/m2
Exclusion criteria ▪ Known distant metastases prior to study entry
▪ Currently participating in any supervised weight loss programmes
▪ Participated in Weight Watchers programme within the previous 3 monthsa
▪ Pregnant womena
▪ Diagnosed eating disordera
▪ Need interpreter to understand English
aCriteria suggested by the WW programme
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dietitian-led support group sessions at the Maggie’s can-
cer support centre, Aberdeen over the course of
14 weeks. The sessions lasted 1–1.5 h and were in groups
of 5–9 participants led by a research dietitian (JC: age
group 40–50 years; British-white; female; registered
dietitian) and a breast care nurse (age group 40–50 years;
British-white; female; registered specialist nurse). The ses-
sions involved PowerPoint presentations using scripts, dis-
plays of various food models and informal learning and
discussion sessions. As both providers had experience in
running group sessions involving patients, they were not
provided with any specific training. A researcher (RN) was
present in all meeting sessions as an observer and a facili-
tator (e.g. taking field notes, serving refreshments). Nei-
ther the group providers nor the participants were blinded
to group allocation.
All materials and discussion topics were generated by
JC based on the findings from the pre-design study
along with her own expert dietetic knowledge and skills
and discussion with the research team and stakeholders
(three breast care specialist nurses). The contents of the
presentation provided by the breast care nurse was gen-
erated and adapted from their previous materials to fit
with the study purpose. Details of the content of these
sessions are given in Additional file 1: Appendix 2.
At the second group meeting (week 2), participants
were given a WW referral pack which included 12 free
vouchers to community meetings plus 16 weeks’ access
to digital content and tools. They were asked to join a
suitable WW group at any location convenient to them
as soon as possible, with other participants from the
group as ‘buddies’ for social support if they wished. It
should be noted that WW referral packs were bought by
the research team directly from the WW and WW team
was not involved in data collection, analysis or interpret-
ation of the research findings.
Overview of the Weight Watchers programme This
programme recommends adoption of energy deficit or
reduced energy diets high in fruit and vegetables and
low in carbohydrates, dairy products and fat for weight
loss maintenance. It also provides a guide for a range of
diets (e.g. vegetarians, gluten free and vegan) and recipes
including a variety of ethnic cuisines (e.g. Indian, Thai,
Italian, American) and fast foods (Weight Watchers®
2015 [71]). Anyone can attend WW community meet-
ings at any group and any location throughout the coun-
try. One-to-one support from the group coach is
available during a weekly weighing session which is usu-
ally followed by a 20-min group discussion, which is cur-
riculum based. Meetings take place in community-based
venues (e.g. church hall, hotel or sports centres) and the
whole session usually lasts for approximately an hour
depending on the size of the group. Moreover,
moderated social media groups, 24/7 live online support
with a coach through expert chat, weekly inspiring con-
tent, e-mails with success stories and contact numbers
of the group coach are provided for continuous support
and motivation for lifestyle change. Core programme ma-
terials are given at the weekly meeting which include rec-
ipes, and tips for healthy nutrition and keeping active.
Physical activity is encouraged throughout the programme.
The weight loss system at the time of this pilot study was
the ProPoints® weight loss system, which enables people to
create an energy deficit for healthy weight loss using a
points-based system; giving people a personalised budget
to spend, with all foods and drinks having a value.
The free vouchers provided in the referral pack were
processed at the WW meeting by the WW coach, who
had not been informed of the pilot study. WW coaches
supported participants as all other participants, includ-
ing those who would come in via the ‘referral’ scheme.
BRIGHT trial participants were told not to inform about
their purpose of attending WW (i.e. trial participants) to
the coach or other attendees at the WW meetings dur-
ing the trial period.
WW group (Weight Watchers referral) All partici-
pants in this group were sent the WW referral pack (12
free vouchers for access to community meetings plus
16 weeks’ access to digital content and tools) by post
and asked to join the programme at a location conveni-
ent to them within 2 weeks of receiving the referral pack
and contact the researcher (RN) to inform of their join-
ing date. Participants had no other contact with the re-
search team until the trial exit visit.
Control group The participants did not receive any
intervention, but at the trial exit (12 weeks following
randomisation) each participant was given the WW re-
ferral pack to use whenever they wished.
Outcomes
Primary outcomes
Primary outcome data were evaluated according to
whether there were any issues that would affect the
feasibility of conducting a future full trial: high retention
rate (ideally ≥ 80% as suggested by previous literature
[38, 35]; no issues with the recruitment (i.e. the process
would identify, invite and recruit the target number of
potential participants in a straightforward manner), ran-
domisation process (i.e. the programme would meet the
purpose of group allocation), the setting for data collec-
tion and delivery of the intervention (i.e. the venue
would be practical for the delivery of intervention and/
or data collection) and the outcome measuring tools (i.e.
tools would be reasonable for the purpose); no barriers
towards adherence to the contents or delivery of
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dietetic-led group sessions (i.e. no substantial modifica-
tions to the protocol would be required); no serious un-
intended consequences (i.e. no hospitalisation,
life-threatening condition or death associated with the
intervention); good meeting attendance rate (≥ 50% as
suggested by other weight loss studies with 12-week
follow-up [32, 33, 70] and low cost. There were no
pre-specified set of criteria to assess all the indicators.
The aim was to evaluate any issues identified in this
pilot and hence, propose solutions if modifiable, for any
future trial.
Secondary outcomes
At trial exit, participants’ weight was measured by a re-
searcher (RN) and they completed the FACT-B ques-
tionnaire at the Maggie’s Centre. At 12 months, all
participants who had completed the trial were sent a let-
ter along with a brief summary of the trial results invit-
ing them to a one-to-one meeting with the study
dietitian (JC) at the Maggie’s Centre. At this meeting,
their weight was measured by a researcher (MN) and
they completed the FACT-B questionnaire. They also
completed an additional short questionnaire (available
on request from the researchers) which asked questions
on the use of the WW vouchers (How many WW
vouchers provided in the study did you use? Have you
attended any more WW meetings since finishing the
vouchers provided in the study? Have you been follow-
ing the WW ProPoints system or any other kind of
weight loss programme since finishing the BRIGHT
study?) and other lifestyle changes including dietary
habits (Have you made any changes to your diet since
finishing the BRIGHT study?) and physical activity (Have
you changed your physical activity in any way since fin-
ishing the BRIGHT study?).
Data collection, management and analysis
All primary outcome data (quantitative and qualitative)
were documented from beginning until trial exit in the
form of field notes: recruitment process (i.e. duration of
the process, time taken to screen and identify potential
eligible patients using medical notes, any challenges
experienced such as availability of the data to assess
eligibility), randomisation process (i.e. whether the ran-
domisation procedure was appropriate for the purpose,
any identified issues), unintended consequences (i.e. any
changes in the processes and/or any incidences that
might impact on the delivery and outcomes of the trial),
issues with the setting (i.e. barriers and facilitators of
using the Maggie’s Centre for the baseline meeting and
delivery of the intervention) and outcome measurement
tools (i.e. whether the weighing scales, and FACT-B were
acceptable for the purpose and any issues with outcome
measurements). Adherence to content and competence
in delivering the dietetic-led sessions was measured and
rated as ‘yes’ or ‘no’, by a researcher (RN) during the
group observations, depending on whether the group
leader performed the expected action during that group
session (i.e. whether the leader adhered to the contents
of the sessions as planned and participants had the
chance to ask questions) (Additional file 1: Appendix 3).
Participants’ attendance at each dietetic-led session was
recorded by the researcher (RN) at the beginning of each
session. Participants in WW Plus and WW group were
requested to self-report their attendance at the WW
meetings to the research team at trial exit. The basic
cost of the programme was calculated as an average per
participant including cost of postage, WW referral pack
and dietitian’s and breast care nurse’s time. Views of the
intervention providers (dietitian and breast care nurses)
were captured through one to one discussion using
structured questions [How did you incorporate the
BRIGHT trial work into your work routine? What bar-
riers have you experienced during delivery of the group
sessions?] and field notes.
All field notes were initially handwritten and then
typed into a Microsoft Word document (including who,
when, where, how and by whom as appropriate) and
kept on a secure server at the University of Aberdeen.
All qualitative data (i.e. field notes from recruitment to
trial entry and discussions with the dietitian and breast
care nurses) was analysed by the researcher (RN) using
narrative analysis to interpret ‘what happened’ in rela-
tion to the feasibility of the trial procedures. This
method of analysis is simple and is concerned with
understanding ‘how and why’ any situation occurs to
explain the entire process systematically (Lieblich,
Amia 1998 [60]).
Most of the analysis was conducted using IBM SPSS
Statistics version 22.0 and carried out by researchers
(RN, MN and SF). Although hypothesis testing in this
type of trial is not recommended, these tests were per-
formed and confidence interval values reported in order
to comment on the promise of the results and inform
future sample size calculations. All tests were two-tailed,
and significance was set at p < 0.05. Baseline characteris-
tics (age, weight, BMI and time since diagnosis) were de-
scribed using median and interquartile range in each
group as these variables were not normally distributed.
A target weight loss of ≥ 5% from baseline weight within
6 months for weight loss programmes is recommended,
as it may lead to reduction in chronic disease risk such
as diabetes and cardiovascular disease [39, 40]. There-
fore, the proportion of participants who had lost 5% or
more of their initial body weight at 12 months was cal-
culated. Scoring of the QoL items was carried out in
SPSS using a syntax file provided by the FACIT organ-
isation (http://www.facit.org).
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Linear mixed effects models were used to assess the
change in weight for each group utilising data from
baseline, 3 and 12 months. This part of the analysis was
conducted by SF using SAS, version 9.3 (SAS Institute
Inc., Cary, NC, USA). The model allows for missing data
under the missing at random assumption as long as at
least one outcome value is available. These models were
fitted with an unstructured covariance with fixed effects
of time, group and a time-group interaction. The same
approach was used to model changes in each of the
quality of life domains. All models were adjusted for
BMI (< 30, ≥ 30 kg/m2), age at baseline (< 60, ≥ 60 years)
and years since diagnosis (< 1, ≥ 1 year). Estimates of
mean change (and 95% CI) at 3 and 12 months from
baseline were calculated along with estimates of differ-
ence in these changes between groups.
Results
Primary outcomes
Feasibility of the procedures
Table 2 provides an overview of the findings of the trial
procedures.
Recruitment Recruitment by one researcher (RN) at
one hospital breast cancer out-patient clinic took
4 months (e.g. it took 4 h to screen 50 clinic notes where
only 10 patients were eligible). The response rate to the
invitation letter was 43% (140/327) of whom 25% (n =
81) were willing to participate and 18% (n = 58) were eli-
gible (Fig. 1). Information on BMI was not available in
the clinic notes so women with BMI < 25 kg/m2 also re-
ceived the letter and some may not have replied as they
knew that they would not be eligible. Therefore, we do
not know the number of eligible women for this trial
and hence the actual response rate of eligible women to
the invitation letter is unknown. At the beginning of the
recruitment, a few women with benign tumours were in-
vited as it was not possible to identify the potential
women from the clinic list. Consequently, following the
first cohort of invitations, to avoid such issues, approval
from the Caldicott Guardian (Medical Director, National
Health Services, Grampian) was sought for the re-
searcher (RN) to access medical notes to identify poten-
tially eligible women.
Twenty-five of the 59 women who did not want to
take part in the trial provided reasons for non-participa-
tion: benign breast disease (n = 8), living too far from
Aberdeen to attend group meetings (n = 7), currently fol-
lowing other weight loss programmes (n = 2), recently
lost weight (n = 2), diagnosed with dementia (n = 2) or
secondary cancer (n = 1), not interested in WW (n =
1), felt they were too old (n = 1) or working night
shifts (n = 1).
Baseline characteristics Forty-seven out of the 58 eli-
gible women (81%) were invited to and attended the
baseline meeting. The remaining 11 women could not
be contacted (e.g. not available to answer a telephone
call, no reply to email or no option to leave a voicemail).
Two of the 47 potential participants were found to be
ineligible following the baseline meeting as one had a
healthy weight when measured and another was sched-
uled to receive chemotherapy.
The median (IQR) age of the participants at recruit-
ment was 61.0 (53.5, 67.0) years with 51% of participants
being over 60 years. Median (IQR) BMI was 30.2 (27.4,
32.7) kg/m2 with 53% of participants having a BMI over
30 kg/m2 (Table 3). The median (IQR) time since cancer
diagnosis was 2.0 (1.0, 4.5) years with all but one of the
participants entering the trial more than 1 year after
their diagnosis. Forty-four participants were White,
British and 1 was African British.
Randomisation A total of 45 participants were allocated
to the 3 arms: 14 to WW Plus group, 16 to WW group
and 15 to control group. The randomisation procedure
used was feasible for the purpose, but it became apparent
the cut-off for years since diagnosis needs to be amended
for future studies. With a median of 2 years, the suggestion
would be < 2/≥ 2 years instead of the < 1/≥ 1 we used here.
Cohort 1 involved 17 participants (WW Plus = 5, WW
group = 6 and control group = 6) and cohort 2 involved
28 participants (WW Plus = 9, WW = 10 and control
group = 9).
Retention Follow-up data (primary and secondary out-
comes) were available for 38 participants [84%; WW
Plus = 13 (93%), WW group = 13 (81%) and control
group = 12 (80%)] at trial exit. Reasons for missing out-
come data were unhappy with the allocated group (WW
group = 2), health issues unrelated to cancer (WW
group = 1), recurrence of cancer (control group = 1),
family-related reason [e.g. lost partner (control group = 2)]
and did not want to attend group sessions in a cancer sup-
port centre (WW Plus = 1). In total, data from 30 partici-
pants [67% of trial completers (WW Plus = 10, WW group
= 11 and control group = 9)] were available at 12 months
post intervention follow-up. Of which, 27/30 women
attended the one-to-one follow-up meeting and 3 provided
measurements by post. Reasons for missing data were
passed away (control group = 1), had surgery (control
group = 1) and did not reply to the invitation (WW Plus =
3; WW group = 2 and control group = 1).
Attendance Twelve of the 14 (85%) participants in WW
Plus group attended all 5 group meetings. Data on at-
tendance at the WW meeting was provided by the par-
ticipants. Eleven participants from WW Plus group
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(78%) and 11 participants from WW group (68%) re-
ported attending all 12 WW meetings.
Adherence At 12 months follow-up, participants from
the WW group (46%, 5/11) reported having attended
WW meetings more often than WW Plus (30%, 3/10) or
control group (25%, 2/8) since finishing the referral pro-
vided in the trial. Seventy percent (7/10) of the WW
Plus, 64% (7/11) of the WW group and 38% (3/8) of the
control group participants reported continuing to follow
the WW ProPoints weight loss system as well as im-
proving their physical activity since finishing the
Table 2 Overview of the findings from the feasibility assessment of the trial procedures
Feasibility indicator What did work well? What did not work well?
How to address these issues in the future (if modifiable)?
Retention This study had a good retention rate (84%). _
Recruitment Staff at the clinic were co-operative and allowed researchers to
screen notes in their busy working atmosphere and to use their
system for printing labels (names and addresses of the
potential participants) which helped to speed up the process.
The process could not meet the target of recruiting 30 women
per arm in 4 month time scale within the resources available.
Solution: More time would be required to achieve target
number of participants if the same procedure were to be used
in a future trial. Reminders could be sent to the
non-responders.
The actual response rate of eligible women to the invitation
letter is unknown as information on BMI was not available in
the clinic notes.
Solution: Weight measurements made at out-patient clinics
should be entered in clinic notes.
Randomisation The overall group allocation process worked well. Median years since diagnosis reported was 2.0 years but the
allocation process used < 1 vs > 1 year since diagnosis.
Solution: A future trial should use median time since diagnosis
(e.g. 2 years) for group allocation.
Unintended
consequences
No serious adverse events were recorded. Two participants were distressed and one withdrew due to
the setting and topics discussed.
Solution: Venue needs to be carefully chosen and topics
related to sensitive issues should be avoided.
Setting Maggie’s centre was feasible for conducting baseline and
end-point meetings and convenient for health professionals
to deliver the dietetic led sessions.
There were problems with using slides in the dietitian-led
group sessions as the room had no blinds or projector screen.
There was a lack of parking space for the participants.
Solution: Issues related to room setting could be addressed
with portable equipment. Another non-hospital venue such
as the CLAN cancer support centre or a community centre
could be used in the future to avoid parking issues.
Data collection
tools
The height measure and weighing scales were easy to use.
The FACT-B QoL questionnaire did not take long to
complete by participants.
The weighing scale could not measure weight above 150 kg.
Solution: Scales with higher weighing capacity could be used.
Some questions of the QoL questionnaire were felt by
participants not to be applicable after a few years of finishing
breast cancer treatments.
Solution: FACT-B could be used with more clear instructions to





All facilitators adhered to the study protocol. Workload and time were recorded as issues for delivering
dietitian led group sessions.
Solutions: Non-health professionals or volunteers could be
trained to deliver the group sessions.
It was not possible to observe WW sessions to report their
fidelity.
Solution: Random sessions could be observed or recorded
to report fidelity.
Also see issues discussed above under setting.
Meeting
attendance
Good attendance rates at dietetic led sessions (85%)
and WW programme (WW Plus = 78% and WW
group = 68%).
Attendance data at WW programme was provided by
participants.
Solution: Participants’ booklet provided by WW could be
assessed for accurate recording of attendance.
Cost WW group was not expensive to run. WW Plus group was expensive to run compared to WW group.
Solution: Non-health professionals or volunteers can be trained
to deliver the group sessions, which can be tested before
inclusion. But then there might not be as good adherence
and fidelity of delivery as observed when ran by a dietitian.
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BRIGHT trial. Finally, 50% (5/10) of the WW Plus, 64%
(7/11) of the WW group and 52% (4/7) of the control
group participants reported having made some other
changes in their diet including reduction of portion size,
eating more fruits and vegetables and reduction of the
amount of ‘fattening’ foods following trial exit.
Setting A private room was used for all one-to-one
meetings. The staff members at the Maggie’s Centre
were very welcoming and helpful. An advantage of using
this setting is that refreshments were offered to the par-
ticipants on their arrival, and if participants arrived earl-
ier than the scheduled time or if the researcher was busy
with another participant, they were kept company by a
member of staff. There were some issues with the setting
of the room for delivering the dietetic-led sessions: no
blinds in the room, which affected the visibility of the
projector screen and hence the room had to be
re-arranged by the research team to avoid this issue.
There was no projector or screen on site available to
use, so the equipment was borrowed from the University
for delivering the sessions; the projector was kept on top
of a table and wires were lying on the floor. Although
this was not ideal, we tried our best to maintain health
and safety standards. Although the centre had their own
parking, it was sometimes not sufficient when there were
other sessions/meetings at the same time as our meet-
ings or other hospital patients parked at the Maggie’s al-
located parking spaces. As a result, on a few occasions
participants were late for their appointments.
Fig. 1 Flow chart showing recruitment and drop-outs at all stages of the pilot BRIGHT trial
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Delivery of the intervention (observation of dietetic-led
sessions from researcher) The first meeting started with
the introduction of the study and team members in-
volved in the whole programme. Some participants
attended the meetings with their partners who socialised
with other partners in the Maggie’s centre while the
women took part in the meetings. Participants discussed
their worries about the weight loss journey due to their
failure of achieving healthy weight following diagnosis.
They mentioned that it was fun answering the true/false
questions, e.g. potatoes belong to the fruit and veg sec-
tion (true or false?). Most of them were surprised that
potato was classed as a starchy food and not a vegetable.
Most of them were also unaware of the amount of
calories hidden in their favourite drinks. They were
engaged with the facilitators and contributed their
knowledge and habits in relation to the topics discussed.
Details of the content of these sessions are available in
Additional file 1: Appendix 2.
The second meeting started with a talk by the breast
care nurse followed by the last half session on physical
activity being led by the dietitian (JC). During the first
half session, participants laughed relating their own ex-
periences with the topics discussed and agreed that they
had experienced most of the symptoms, e.g. increased
appetite, altered taste and less activity. One participant
was emotionally distressed during the discussion of
changes in body image (i.e. due to hair loss and/or mast-
ectomy) and relationships and left the room for a short
period of time. It was mentioned that she felt distressed
during the discussion about relationship issues as it
reminded her about her personal experiences at the time
of receiving treatments. Participants mentioned that this
type of information (i.e. tips for maintaining a positive
body image, prosthesis/underwear) would have been
helpful soon after diagnosis or finishing treatment, as
the information received during treatment was too much
to take in. During the physical activity talk, participants
were fully engaged and agreed that 30 min of physical
activity out of 1440 min a day is easily achievable with
self-motivation. At the end of this session, on receiving
the WW vouchers, participants looked very happy and
excited to start something new.
At the beginning of the third meeting, participants dis-
cussed their experience of the WW meetings with other
group members and the dietitian (JC). Some took their
folder, leaflet and recipes provided by WW to this meeting
and realised that they had all received different resources
in the same week as they all attended different WW meet-
ings. One participant mentioned that she felt she was be-
ing treated differently by the WW leader as she was given
a red folder and the rest of the members of WW had a
blue folder, and the reason given by the WW leader was
‘you are special’. During the discussion, it emerged that all
participants (from our study) had received a red folder sig-
nifying participation in a referral pack scheme.
This meeting covered topics related to food labels, rec-
ommended portion sizes, calorie counting and tips for
portion control. Most participants mentioned that differ-
ent supermarkets use different labels and they experienced
that these labels are difficult to read and understand.
Therefore, discussion on labels (i.e. colour-coded informa-
tion on how to read a label) for similar type of products
were found to be very useful. Most participants agreed re-
garding the reasons discussed why people eat more than
they need (e.g. habit, satisfaction, taste, reluctant to waste
food and larger restaurant portions) and mentioned that
tips for eating less (e.g. listen to hunger; if a portion is
large share with a friend) would help them to change
habits. However, some said that they already knew most of
these topics being discussed, but they had never had the
motivation to follow these to change to a healthy lifestyle.









Age at baseline (years)
Median [IQR (25th, 75th)] 61.0 (53.5, 67.0) 60.0 (53.7, 67.5) 60.0 (51.0, 66.0) 61.0 (52.0, 70.1)
Menopausal status at diagnosis (%)
Pre-menopausal 35.6% 28.6% 43.8% 33.3%
Post-menopausal 64.4% 71.4% 56.3% 66.7%
Time since cancer diagnosisa (years)
Median [IQR (25th, 75th)] 2.0 (1.0, 4.5) 2.0 (1.8, 5.0) 2.0 (1.0, 3.8) 2.5 (1.0, 5.0)
Baseline weight (kg)
Median [IQR (25th, 75th)] 76.6 (70.9, 85.1) 76.6 (69.9, 85.2) 77.2 (72.6, 85.3) 76.6 (70.2, 89.5)
BMI at baseline (kg/m2)
Median [IQR (25th, 75th)] 30.2 (27.4, 32.7) 30.1 (27.0,33.1) 30.4 (27.7, 32.9) 30.2 (26.5, 33.1)
IQR interquartile range
aTime interval between breast cancer diagnosis and study entry
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During the fourth meeting, food models were dis-
played on two tables for the participants to see and dis-
cuss. The dietitian (JC) started the session by asking
how they were getting on with WW and recapping the
previous three talks. All participants in cohort 1 had
2 weeks off from WW during Christmas time as no clas-
ses were run over that period, and they all mentioned
that they found it very difficult to lose weight during
that time. The dietitian (JC) gave a talk on hidden calo-
ries (topics covered various names of sugars to identify
in food labels such as fructose; high vs. low fat foods)
and how to avoid these calories (e.g. changing to
semi-skimmed milk could save 60 cal a day or 420 cal a
week) followed by looking at the food models and dis-
cussion. During the slide show on fats, some mentioned
swapping cooking ingredients with healthy options such
as margarine and non-creamy sauce, although some
mentioned not liking the taste. One participant said that
she thought gin and tonic had fewer calories than a glass
of wine and was surprised at seeing the model which
showed that both contain similar calories. They were
also shocked to find out that Heinz tomato soup con-
tains a lot of sugar.
During the last meeting, participants were asked about
their whole experience of the last four meetings and if
they had any queries related to diet, physical activity and
weight loss. They discussed how much they had lost so
far based on the assessment by WW and how they were
managing their lifestyle. Most participants mentioned
that they tried to follow a healthy lifestyle based on what
they have learnt from the dietetic-led group meetings ra-
ther than strictly following the WW ProPoints® system
suggested by the WW programme. They also discussed
that if their weight was assessed in every group meeting
by the dietitian (JC), they would have been more moti-
vated to lose the weight. They mentioned that the quiz
session was fun and it captured their understanding of
the previous sessions. They also enjoyed and had a laugh
together when JC disclosed the right answers to the quiz
questions. The session ended by thanking the partici-
pants for taking part in the trial and a plant was given to
each participant and flower bouquets to the 1st, 2nd and
3rd prize winners of the quiz. All participants expressed
enjoying every session and being disappointed that the
trial had concluded.
Qualitative data collected confirmed the fidelity in that
the trial was delivered as intended by the researchers
and also it adhered to the study protocol including dur-
ation of contact time (length of time of intervention
period), and intervention contents. No modifications in
trial procedures were required for cohort 1 or 2. The
dietitian and breast care nurses had adequate expertise
and skills to answer participants’ queries and make the
sessions enjoyable.
It was not possible to observe WW sessions to report
their fidelity due to the different timings and locations at
which our participants attended. However, the organisa-
tion have a matrix of QA and audit in place to oversee
fidelity of programme delivery in the network of 6000
meetings in the UK. However, these data were not made
available to our research team.
Both facilitators (dietitian and breast care nurse) dis-
cussed how they had incorporated this trial work into
their existing workloads. As an example, the breast care
nurse team required advanced notice (e.g. minimum of
2 weeks) of the scheduled day and time to take time out
of their routine job to deliver the session. It might be a
problem for them to deliver the intervention out of
working hours such as evenings or weekends.
Outcome measurement tools The height measure and
the weighing scale were easy to use. The weighing scale
could not measure weight above 150 kg and hence one
participant had to be taken to a different building to
measure her weight on a suitable scale. In relation to the
FACT-B questionnaire, it took on average 8 min to
complete the questionnaire by the participants. Partici-
pants had no problem filling in the questionnaire. There
were very few missing data for the questions except for
‘I feel sexually attractive’ (n = 2), ‘I feel close to my part-
ner (or the person who is my main support)’ (n = 2), ‘I
am bothered by side-effects of treatment’ (n = 1) and ‘I
am bothered by hair loss’ (n = 1). The latter two ques-
tions were thought to be not applicable after a few years
of finishing breast cancer treatments. However, 12 par-
ticipants missed out the question ‘I am satisfied with my
sex life’ as it was felt to be not applicable—but this was
not a problem as there was an option to skip this ques-
tion and go to the next section. The researcher had to
read out the questions word for word for three partici-
pants due to issues with poor eyesight and/or forgetting
reading glasses.
Cost WW Plus group (£167.72 per participant) was
more expensive to run than the WW group (£59.31 per
participant) or control group (£57.72 per participant),
due to the additional cost of the facilitators to run the
dietitian-led sessions.
Unintended consequences Only two unintended con-
sequences were recorded: one participant from WW
Plus group did not want to continue participating in the
trial as the cancer support centre and topics discussed in
the dietetic-led group meeting related to ‘cancer and re-
lationship issues’ had reminded her of cancer diagnosis.
Another participant also from the WW Plus group was
upset during the talk on changes in body image and rela-
tionships (discussed earlier) but remained in the trial.
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Discussion on sensitive issues, if unrelated to trial aim
and objectives such as issues with hair loss or relation-
ship, should be avoided.
Secondary outcomes
Changes in body weight Table 4 describes the results
of the mixed effects model. Both WW Plus and WW
group showed significant (p < 0.001) weight change from
baseline to 3 months, but the control group did not
(Table 4). Around 58% participants in WW group and
37% in WW Plus group achieved clinically important ≥
5% loss of initial weight at trial exit. The change in
weight from baseline to 12 months was significant for the
control group (− 4.22 kg, received WW referral following
trial exit) and the WW group (− 5.11 kg), but was no lon-
ger significant for the WW Plus group (− 1.22 kg).
However, 40% of the WW Plus group, 64% of the WW
group and 56% of the control group lost ≥ 5% of their
baseline weight by 12 months. There were no significant
differences found in weight changes in any of the inter-
vention arms (WW Plus, p = 0.536; WW group, p = 0.240
or control group, p = 0.522) between batch 1 vs. batch 2.
Changes in QoL At trial exit and 12 months follow-up,
in the adjusted model, all three groups showed statisti-
cally significant improvements from baseline in various
subscales of the FACT-B (Table 5). The WW Plus group
showed statistically significant improvements at trial exit
on the Functional Well-being (FWB, p = 0.023), Func-
tional Assessment of Cancer Therapy-General (FACT-G,
p = 0.020), Breast Cancer Specific (BCS, p < 0.001) sub-
scales, Total Trial Outcome Index (TOI, p = 0.003) and
the overall scale of FACT-B (p = 0.002). The WW group
showed statistically significant improvements at trial exit
in Physical Well-being (PWB, p = 0.001), Emotional
Well-being (EWB, p = 0.038), FACT-G (p = 0.006), BCS
(p < 0.001) and TOI (p < 0001) sub-scales, while the con-
trol group showed statistically significant improvements
at trial exit in the FACT-G (p = 0.023) and overall
FACT-B (p = 0.026). At 12 months follow-up, the WW
group showed statistically significant improvements
from baseline on the PWB (p = 0.029), BCS (p = 0.008)
and TOI (p = 0.006) sub-scales.
A minimally important difference (MID) on a QoL
measure corresponds to the smallest difference in score
in the domain of interest that patients perceive as im-
portant, and which would lead the clinician to consider
a change in patient’s management (Eton, D.T. 2004
[61]). The suggested MID for the FACT-B scale are BCS
= 2–3 points, TOI = 5–6 points, FACT-G total = 5–6
points and FACT-Breast total = 7–8 points (Eton, D.T.
2004 [61]) (Table 5). At 12 months, the WW group
achieved and maintained the MID in FACT-G, BCS,
FACT-B and TOI, whereas WW Plus maintained it for
BCS only.
Discussion
Overall, this pilot trial suggested that a larger trial would
be feasible as the retention rate was ≥ 80% and meeting
attendance rate was ≥ 50%; no serious adverse events
were recorded; and providing WW vouchers incurred
low cost. The secondary outcomes also showed promise
to support a larger, definitive trial. Suggested modifica-
tions to any future trial include assuring adequate blind-
ing throughout the process, the cut-off for years since
diagnosis should be < 2/≥ 2 years for the randomisation
process, a weighing scale with higher weighing capacity
should be used, and clear instructions for completing
FACT-B should be provided to avoid missing data. If the
same setting is used in the future, the issues related to
delivering the interventions need to be addressed. Due
to resource limitations, the recruitment was limited to
one centre in Aberdeen and the target sample size could
not be achieved in the available time. More time or add-
itional centres would be required to recruit sufficient par-
ticipants within a given time frame in future larger RCT.
A key finding of the BRIGHT pilot trial is that there is
little evidence to support the addition of breast
cancer-tailored dietitian-led group support with WW re-
ferral due to its less promising outcomes, higher costs,
as well as other implementation barriers suggested by
the facilitators (i.e. lack of time and staff issues). The
BRIGHT study has made an important contribution to
Table 4 Mean weight loss over 12 months after fitting a linear mixed model








Weight change (95% CI) (kg) − 3.67 (− 5.67, − 2.07) − 6.03 (− 7.61, − 4.44) + 0.19 (− 1.45, 1.83)
p value p < 0.001 p < 0.001 p = 0.815
Baseline—12 months
Weight change (95% CI) (kg) − 1.22 (− 4.42, 1.98) − 5.11 (− 8.18, − 2.05) − 4.22 (− 7.55, − 0.88)
p value p = 0.436 p = 0.002 p = 0.015
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the existing evidence of feasibility and pilot studies for
weight loss in breast cancer patients. Evaluation of the
BRIGHT trial process was useful for the purposes of
assessing feasibility assessment and highlighting where
potential threats to the internal and external validity of a
large-scale RCT are likely to occur.
Our study shows promise, as over half of the partici-
pants in the WW group (58%) compared to 37% in the
WW Plus group achieved a clinically important ≥ 5%
loss of initial weight at 12 weeks. It is conceivable that
more participants would have achieved clinically mean-
ingful weight loss if the intervention was continued for
longer such as up to 6 months or more [41].
At 12-month follow up, ≥ 40% of participants in all three
groups achieved ≥ 5% weight loss. These findings are
higher than the findings of Jolly et al.’s study (the Lighten
Up trial) of a general population which involved eight pro-
grammes (WW; Slimming World; Rosemary Conley;
group based, dietetics-led programme; general practice
one-to-one counselling; pharmacy-led one-to-one coun-
selling; choice of any of the six programmes and a com-
parator group), delivered for 12 weeks [32]. In that trial,
the highest proportion of participants (31%) who sustained
≥ 5% weight loss from baseline at 12 months was from the
WW group as compared to the other trial groups. Other
RCTs of WW programmes with non-cancer patients have
shown lesser weight loss-maintenance, although these in-
terventions were of longer duration, compared to the
BRIGHT trial [33, 42, 43]. A possible explanation is that
BRIGHT trial participants were breast cancer survivors
and hence, were more motivated to lose extra weight and
maintain it to improve breast cancer-related prognosis. It
is also possible that some participants had a recurrence of
their cancer, and were unaware of this, which might have
contributed to weight loss.
A study of breast cancer survivors in the USA (mean
BMI 35.5 ± 3.9 kg/m2, mean age 51.7 ± 8.4 years), using
either WW, intensive individual dietitian support for
12 months or both, found that participants receiving
both interventions lost almost four times more weight
than the group using WW alone at 12 months [34].
However, the extra support and 2 weeks longer interven-
tion period had no impact on sustaining the weight loss
in the WW Plus group after trial exit. Another rando-
mised trial of overweight and obese adults in the USA
(90% women, mean BMI 36.2 ± 5.5 kg/m2, mean age
49.7 ± 9.2 years) found that those receiving WW
programme alone lost significantly more weight at
48 weeks than those receiving WW programme follow-
ing group-based behavioural counselling [44]. Some par-
ticipants reported that the transition to WW was
difficult following the counselling due to differing ap-
proaches towards weight loss and changes in group size
and leadership disrupting their weight loss progress [44].
This may indicate that the breast cancer-tailored
dietitian-led support group sessions in our study reduced
the likelihood of the participants adhering to the WW
programme which could similarly be due to issues
Table 5 Changes in Quality of Life scores
Table showing changes in QoL scores between baseline and 12months (linear mixed model) for Physical well-being (PWB), Social/Family well-being (SWB), Emotional well-being
(EWB), Functional well-being (FWB), Functional Assessment of Cancer Therapy–General (FACT-G = PWB + SWB + EWB + FWB) and Breast Cancer specific (BCS) subscales, as well
as the overall scale of Functional Assessment of Cancer Therapy—for breast cancer (FACT-B = FACT-G + BCS) and the Trial outcome index (TOI = PWB + FWB + BCS)
A higher value indicates greater improvement. Suggested minimally important differences (MID) for the scale: BCS = 2–3 points, TOI = 5–6 points,
FACT-G total = 5–6 points and FACT-Breast total = 7–8 points (Eton, D.T. 2004 [61]). The values shaded in grey highlighting the subscales that obtained MID
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related to transition between groups. On the other hand,
the WW only group followed one approach which may
have led to improved weight loss maintenance.
Previous research suggested that group interventions
for cancer patients are useful to reduce symptoms of de-
pression and anxiety, improve social support and
self-efficacy for coping, reduce pain and improve QoL
among survivors [45, 46]. Our pilot study did not sug-
gest any benefits of offering breast cancer-tailored
dietitian-led group support in addition to WW referral.
Psychological distress and depressive symptoms are typ-
ically highest in the first 6 months following cancer diag-
nosis and then usually decline over time as women
adjust to the initial shock of diagnosis and acute effects
of cancer treatment (Bower J.E. 2008 [62]). The rates of
psychological symptoms of disease-free breast cancer
survivors are comparable to women in the general popu-
lation, although a subset of women may continue to ex-
perience negative symptoms for years after treatment
(Bardwell, Wayne A 2006 [63]). Therefore, it is possible
that as most participants joined the BRIGHT trial at
least 1 year post-diagnosis, their psychological symptoms
(e.g. feeling less optimism, having lower self-esteem)
were less severe than closer to the diagnosis. Other stud-
ies suggest that health professional’s support and/or peer
group support in cancer patients may add benefit, but
this needs to be weighed against the costs depending on
existing resources [34]. The WW Plus arm incurred
higher cost in delivering this intervention compared to
other arms due to the involvement of a dietitian and a
breast care nurse. On the other hand, providing WW re-
ferral was inexpensive and effective for weight loss main-
tenance and improving QoL without the support of the
breast cancer peer group and health professionals.
Therefore, it has raised opportunities for further re-
search, namely running of a definitive trial involving a
WW group and a control for this patient group.
Strengths and limitations
The strength of the study is that we have demonstrated
feasibility of the trial procedures in a definitive trial and
shown that there is little evidence to suggest proceeding
with the WW Plus arm in a future definitive trial.
Another strength of the study is that we did not use
self-reported measures, except for three participants at
12 months follow-up who could not attend and hence
sent by post, for weight changes to avoid the drawbacks
of under-reporting for weight or BMI and over-reporting
for height [47, 48].
A limitation of this study is that it was mainly con-
ducted by one individual with great enthusiasm for the
project, and results achieved in these types of trials
might not give a true picture of a weight loss interven-
tion in a multi-site trial or a real-world setting. This may
be due to protocol adherence and enthusiasm in the trial
participants and trial centres or because our participants
were motivated to participate in a weight loss programme
as invited by a breast consultant and/or the trial was
funded by a cancer charity or for the good of others
[49, 50]. Therefore, we recommend endorsement of the
programme by a breast care consultant and breast can-
cer charity in future trials or during implementation.
However, the participants seemed satisfied with the way
in which the intervention was delivered; otherwise, it is
unlikely that they would have continued and conse-
quently, the intervention would have had a poor reten-
tion rate and been less likely to achieve any positive
outcomes [51, 52]. Furthermore, few follow-up time
points for outcome measures were used in this trial to
reduce burden on participants and improve retention.
We were unable to recruit the targeted number of par-
ticipants, due to limited time and resources available. In
our trial, some ineligible women were invited because
BMI was not recorded in medical records in outpatient
clinics. Therefore, we recommend measuring and re-
cording weight and BMI of breast cancer patients during
every clinic visit should be performed to increase effi-
ciency for future research. In addition, as body weight is
an important prognostic factor, health professionals and
researchers should have access to these data.
Secondary outcome data need to be interpreted with
caution because this pilot stage was not fully powered to
test for differences in outcomes (Shanyinde M. 2011 [58]).
Adequately powered RCTs with long-term follow-up are
needed to observe any differences in weight-loss and im-
pact on survival. In future trials, we recommend random-
isation, allocation and outcome assessment should be
conducted by an independent person not involved in the
trial design, recruitment and/or its delivery. The suggested
costs of the programme were the direct costs of each
intervention arm but we have not determined the cost to
the participants of attending the programme or if they
chose to purchase any products from the WW
programme (they do not need to, but may have chosen to
do so). In future trials, cost-effectiveness should be
assessed and reported to enable the decision making
process for future implementation of the programme.
Possible next steps
In the future, a pragmatic single-blind multi-site weight
loss maintenance trial should be considered based on
the findings of the BRIGHT pilot trial and following dis-
cussions with experts in this area and various stake-
holders including WW. Based on current findings, a
hypothesis could be proposed as follows: a greater
proportion of participants in the WW group will achieve
≥ 5% weight loss at 12 weeks and will maintain the weight
loss at 15 months (or 12 months post-intervention)
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compared to the control. As a 12-week referral scheme is
already in use by primary care in the UK, the authors sug-
gest keeping the duration of the intervention as 12 weeks.
The ultimate aim of most weight loss studies is to main-
tain initial weight loss over a long period of time (Borek,
Aleksandra J 2015 [64]) ideally 12 months or longer [15]
(SPH 2010 [65]). The WW programme is available in the
community for weight loss and maintenance; therefore, the
participants would be encouraged to follow the
programme, attending group meetings and/or using the on-
line resources. This would also measure the impact of con-
tinuation of attending WW meetings by participants’ own
costs on sustainability of the trial (i.e. providing 12 week
free access to WW meetings). Furthermore, the WW
programme is suitable for a wide range of people with dif-
ferent cultural and/or dietary restrictions and therefore, no
major adaptation would be required if participants from
different ethnicity are to be recruited in the future RCT.
Participant-related outcomes would be measured at
baseline, 3 months, 12 and 15 months post-randomisation.
Recruitment of sufficient participants in an efficient
manner is still a major challenge to RCTs (Donovan,
Jenny L 2016 [66]). To optimise recruitment and enrol-
ment in the future, breast consultants or breast care
nurses and cancer support centres from a number of
sites could be involved as recruitment through oncolo-
gists’ office (33%) or cancer support centres (50%) has
shown better enrolment of participants compared to
mailing from research office (14% in the BRIGHT pilot
trial) (Pinto Bernardine M 2004 [67]; Pakilit, Amber T
2001 [68]). Pro-active recruitment during clinic visits
may also result in inviting only potentially eligible partic-
ipants, lowering cost per enrolled participant (due to ex-
clusion of staff time to assess eligibility and postal costs)
and achieving a better response rate by gaining accept-
ance and trust from their health professionals for partici-
pating in a RCT (Samelson, E.J. 2008 [69]; Donovan,
Jenny L 2016 [66]).
To demonstrate clinically meaningful 5% weight loss at
12 months, a range of sample sizes are suggested based on
the BRIGHT pilot trial and another weight loss study, the
Lighten-UP trial (targeted weight loss-maintenance using a
range of commercial and primary care led programmes for
12 weeks in the UK and followed the participants for
1 year) [32] (Additional file 1: Appendix 4). These calcula-
tions reflect on the proportion of participants in the con-
trol and intervention arm achieving 5% weight loss
maintenance at 12 months post-intervention follow-up
(conducted by SF using nQuery Sample size calculator, and
90% power and 5% significance two-tailed test). As an ex-
ample, using more realistic figures from the Lighten-Up
trial compared with possibly overly optimistic higher values
from our study, if 20% of the control group (17% in the
Lighten-Up trial) and 50% of the intervention group (64%
WW group in BRIGHT and 31% WW group in the
Lighten-Up trial) achieve ≥ 5% weight loss, then 58 partici-
pants per group would be needed, so total n = 116. As-
suming dropout would be 30%, then the total number
recruited needs to be 116/0.7 = 166, which is n = 83 per
group. The sample size will inflate if the control group
success rate is higher and if the difference between control
and intervention is smaller.
Conclusions
The BRIGHT trial procedures were feasible, with minor
modifications. This pilot trial indicates the benefits of pro-
viding free WW vouchers for weight loss maintenance
and improving QoL but provided no evidence that includ-
ing a dietitian-led group support as delivered in this study
would add any extra value. Further research on providing
free WW vouchers with long-term (≥ 10 years) follow-up
should be assessed for its sustainability on weight loss
maintenance, benefit on survival and other health out-
comes in women treated for breast cancer.
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